8-K: Xilio Therapeutics Initiates Phase 2 for XTX301, Secures $17.5M Milestone

Xilio Therapeutics announced the initiation of Phase 2 for its tumor-activated IL-12, efarindodekin alfa (XTX301), and achieved a $17.5 million development milestone from Gilead, extending its cash runway.

Summary

• Initiated patient dosing in Phase 2 of an ongoing Phase 1/2 clinical trial evaluating efarindodekin alfa (XTX301), a tumor-activated IL-12, as a monotherapy in patients with certain advanced solid tumors.
• Achieved a $17.5 million development milestone payment under the exclusive license agreement with Gilead Sciences, Inc. (Gilead).
• Updated data from the ongoing Phase 1 trial for efarindodekin alfa demonstrated promising anti-tumor activity, including two partial responses (one confirmed, one unconfirmed) in late-line patients with advanced solid tumors.
• Efarindodekin alfa (XTX301) has been generally well-tolerated in Phase 1, with the majority of treatment-related adverse events being Grade 1 or 2.
• Cash and cash equivalents as of June 30, 2025, were $121.6 million.
• Anticipates that its cash and cash equivalents as of June 30, 2025, together with the $17.5 million development milestone, will be sufficient to fund operating expenses and capital expenditure requirements into the first quarter of 2027.
• Expects to receive the $17.5 million development milestone payment by the fourth quarter of 2025.
• Recently selected an initial Recommended Phase 2 Dose (RP2D) and schedule for efarindodekin alfa.
• Completed enrollment in Phase 1A monotherapy dose escalation, with evaluation ongoing, and continues to enroll patients in the Phase 1B monotherapy dose expansion.
• The Phase 2 portion of the trial is anticipated to enroll approximately 40 patients in specific tumor types at multiple sites in the United States.
• Under the Gilead license agreement, Xilio is responsible for conducting clinical development for efarindodekin alfa through the initial Phase 2 portion of the trial.
• Gilead can elect to transition responsibilities for development and commercialization of efarindodekin alfa after Xilio delivers a specified clinical data package, subject to a $75.0 million transition fee.
• If Gilead exercises its option, Xilio will be eligible to receive up to $500.0 million in specified development, regulatory, and sales-based milestones, and tiered royalties ranging from high single digits to mid-teens on annual global net product sales.

Sentiment

Score: 8

Explanation: The filing reports significant positive clinical progress with the initiation of Phase 2 for XTX301, coupled with encouraging Phase 1 data showing anti-tumor activity and a favorable safety profile. The achievement of a $17.5 million milestone payment from Gilead and the resulting extension of the cash runway into Q1 2027 substantially de-risk the company's near-term financial position and validate its technology. The potential for substantial future milestones and royalties further enhances the positive outlook.

Positives

• Initiation of the Phase 2 clinical trial for efarindodekin alfa (XTX301) marks significant progress in the development pipeline.
• Achievement of a $17.5 million development milestone from Gilead provides non-dilutive funding and validates the program.
• The milestone payment extends the anticipated cash runway into the first quarter of 2027, significantly improving financial stability.
• Phase 1 data for XTX301 demonstrated encouraging anti-tumor activity, including two partial responses in late-line patients with advanced solid tumors.
• XTX301 exhibited a generally well-tolerated safety profile in Phase 1, with most treatment-related adverse events being Grade 1 or 2, which is favorable for an IL-12 therapy.
• Management believes the data provides further clinical validation for its proprietary masking technology and approach, which is considered best-in-class.
• Potential for substantial future milestone payments (up to $500.0 million) and tiered royalties from Gilead if the option is exercised, indicating significant long-term value.

Risks

• Risks and uncertainties related to market and other conditions, and the impact of general economic, industry, or political conditions.
• Risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting, or completing preclinical studies and clinical trials and the timing and results of such studies or trials.
• The potential for delays in any current or planned preclinical studies or clinical trials or the development of current or future product candidates.
• The ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates.
• Initial, preliminary, or interim preclinical or clinical data or results may not be replicated in or predictive of future preclinical or clinical data or results.
• The ability to successfully demonstrate the safety and efficacy of product candidates and gain approval on a timely basis, if at all.
• Results from preclinical studies or clinical trials for product candidates may not support further development of such product candidates.
• Actions of regulatory agencies may affect the initiation, timing, and progress of current or future clinical trials.
• The ability to obtain, maintain, and enforce patent and other intellectual property protection for current or future product candidates.
• The need to obtain additional cash resources to advance its pipeline of tumor-activated I-O molecules.
• The impact of international trade policies on the business, including U.S. and China trade policies.
• The ability to maintain collaboration or partnership agreements with AbbVie, Gilead, and Roche.

Future Outlook

Xilio Therapeutics anticipates its current cash and cash equivalents, combined with the $17.5 million development milestone from Gilead, will be sufficient to fund operating expenses and capital expenditure requirements into the first quarter of 2027. The company expects to receive the $17.5 million payment by the fourth quarter of 2025. Future potential includes a $75.0 million transition fee and up to $500.0 million in additional milestones, plus tiered royalties, if Gilead exercises its option to take over development and commercialization of efarindodekin alfa.

Management Comments

• "We are pleased to announce the initiation of the Phase 2 clinical trial for efarindodekin alfa (XTX301), a tumor-activated IL-12, in patients with advanced solid tumors." Ren Russo, Pharm.D., president and chief executive officer of Xilio.
• "The achievement of this important milestone highlights the promising Phase 1 data demonstrated for efarindodekin alfa to date, including two partial responses in late-line patients with advanced solid tumors and a generally well-tolerated safety profile." Ren Russo.
• "These data also provide further clinical validation for our proprietary masking technology and approach, which we believe is best-in-class and has potential across a wide range of therapies and modalities." Ren Russo.
• "We are encouraged by the totality of data observed to date for efarindodekin alfa (XTX301) as a monotherapy in patients with advanced solid tumors, and we are excited for the potential that IL-12 has to treat a broad range of tumor types." Bernard Fine, vice president, oncology early development at Gilead.
• "We look forward to advancing the efarindodekin alfa (XTX301) program in the Phase 2 trial in partnership with Xilio." Bernard Fine.

Industry Context

The development of tumor-activated immuno-oncology therapies like XTX301 represents a significant trend in cancer treatment, aiming to improve efficacy and reduce systemic side effects by localizing activity within the tumor microenvironment. IL-12 is a cytokine with known anti-tumor properties, and Xilio's 'masked' approach seeks to overcome historical toxicity challenges. The partnership with Gilead, a major pharmaceutical company, validates Xilio's technology and strategy, aligning with the industry's increasing focus on strategic collaborations for de-risking and accelerating drug development.

Comparison to Industry Standards

• The achievement of a Phase 2 milestone and extension of cash runway are positive indicators in the highly capital-intensive biotechnology sector, where many early-stage companies face significant funding challenges.
• Two partial responses in late-line advanced solid tumor patients from a Phase 1 trial are encouraging, especially for a monotherapy, and compare favorably to typical early-stage oncology trial outcomes which often focus primarily on safety. For example, many Phase 1 trials for novel agents might only show stable disease or minor responses.
• A "generally well-tolerated safety profile" with mostly Grade 1 or 2 adverse events is a strong positive for an IL-12 therapy, as systemic IL-12 has historically been associated with significant toxicity, limiting its clinical utility. This suggests Xilio's tumor-activated masking technology is effectively mitigating systemic side effects, a key differentiator compared to unmasked IL-12 approaches.
• The potential for up to $500 million in milestones and tiered royalties from Gilead is a substantial deal for a clinical-stage biotech, reflecting strong confidence from a major pharmaceutical partner in the asset's potential, comparable to other high-value early-stage oncology licensing agreements.

Stakeholder Impact

• Shareholders: Positive impact due to clinical progress, non-dilutive funding, extended cash runway, and validation of technology by a major partner, potentially increasing share value.
• Patients: Potential for a new, more effective, and better-tolerated treatment option for advanced solid tumors.
• Employees: Increased job security and potential for continued research and development activities due to extended funding.
• Gilead Sciences: Progress in a partnered asset, potentially leading to future commercialization opportunities.

Next Steps

• Continue evaluation of patients in Phase 1A monotherapy dose escalation.
• Continue enrollment of patients in the Phase 1B monotherapy dose expansion.
• Enroll approximately 40 patients in specific tumor types for the Phase 2 portion of the trial.
• Receive the $17.5 million development milestone payment by the fourth quarter of 2025.
• Xilio to conduct clinical development for efarindodekin alfa through the initial Phase 2 portion.
• Deliver a specified clinical data package for efarindodekin alfa to Gilead.
• Gilead may elect to transition development and commercialization responsibilities for efarindodekin alfa, subject to terms and a $75.0 million transition fee.

Key Dates

Recommendation

The initiation of a Phase 2 trial for XTX301, coupled with encouraging Phase 1 efficacy data (two partial responses in late-line patients) and a favorable safety profile for an IL-12 agent, represents significant de-risking for a clinical-stage biotech. The achievement of a $17.5 million milestone payment from Gilead, a major pharmaceutical partner, not only provides non-dilutive capital but also extends the company's cash runway into Q1 2027, addressing a critical concern for early-stage biotechs. This financial stability, combined with the potential for substantial future milestones (up to $500 million) and royalties, validates Xilio's proprietary masking technology and significantly enhances the long-term value proposition. The positive clinical and financial updates suggest a strong upward trajectory for the company, making it an attractive investment.

Keywords

Xilio Therapeutics, XTX301, Efarindodekin Alfa, IL-12, Immuno-oncology, Solid Tumors, Phase 2 Clinical Trial, Gilead Sciences, Biotechnology, Oncology, Drug Development, Milestone Payment, Cash Runway, Clinical-stage, Tumor-activated